⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6115088 | 0.81 | FDPS (0.32) | — | |
| SCHEMBL18221756 | 0.75 | — | — | |
| SCHEMBL18221785 | 0.74 | — | — | |
| SCHEMBL686782 | 0.71 | — | — | |
| SCHEMBL9231823 | 0.71 | — | — | |
| SCHEMBL136992 | 0.71 | — | — | |
| SCHEMBL3852620 | 0.71 | — | — | |
| SCHEMBL17138345 | 0.71 | — | — | |
| SCHEMBL17138330 | 0.71 | — | — | |
| SCHEMBL27438996 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5952478-A | Intermediates for dinucleotide and oligonucleotide analogues | NOVARTIS FINANCE CORPORATION (US) | 1999-09-14 | — | — | US | claimed |
| EP-0778843-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | Novartis AG (CH) | 1997-06-18 | — | — | EP | claimed |
| WO-1996008503-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1996-03-21 | — | — | WO | claimed |
| EP-4373832-A1 | PROCESSES OF MAKING ONAPRISTONE AND INTERMEDIATES THEREOF | Context Biopharma Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023003863-A1 | PROCESSES OF MAKING ONAPRISTONE AND INTERMEDIATES THEREOF | CONTEXT BIOPHARMA INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023000135-A1 | PROCESSES OF MAKING ONAPRISTONE AND INTERMEDIATES THEREOF | CONTEXT BIOPHARMA INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| CN-106146851-B | Photocurable composition and cured product containing same | 信越化学工业株式会社 | 2020-10-23 | — | — | CN | disclosed |
| EP-3093303-B1 | PHOTOCURABLE COMPOSITION AND CURED PRODUCT | SHINETSU CHEMICAL CO (JP) | 2019-08-28 | — | — | EP | disclosed |
| US-20160333171-A1 | PHOTOCURABLE COMPOSITION AND CURED PRODUCT | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| EP-3093303-A1 | PHOTOCURABLE COMPOSITION AND CURED PRODUCT | Shin-Etsu Chemical Co., Ltd. (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-7534780-B2 | Estradiol prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-05-19 | — | — | US | disclosed |
| US-5670489-A | USEFUL IN TREATMENT OF DISEASES WHICH ARE MODULATED BY PROTEINS, OR IN TREATMENT OF VIRUSES SUCH AS INFLUENZA, HERPES, AND HIV | NOVARTIS CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0778843-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | Novartis AG (CH) | 1997-06-18 | — | — | EP | disclosed |
| WO-1996026207-A1 | THIAZOLIDINE AND OXAZOLIDINE INDOLES WITH HYPOCLYCEMIC ACTIVITY | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-29 | — | — | WO | disclosed |
| US-5508270-A | Nucleoside phosphinate compounds and compositions | CIBA-GEIGY CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1996008503-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1996-03-21 | — | — | WO | disclosed |
| US-5466677-A | Dinucleoside phosphinates and their pharmaceutical compositions | CIBA-GEIGY CORPORATION (US) | 1995-11-14 | — | — | US | disclosed |
| EP-0614906-A1 | Mononucleotide analogues and intermediates therefor | CIBA-GEIGY AG (CH) | 1994-09-14 | — | — | EP | disclosed |
| EP-0614907-A1 | Dinucleotide and oligonucleotide analogues | CIBA-GEIGY AG (CH) | 1994-09-14 | — | — | EP | disclosed |
| EP-0374095-A2 | Piperidine derivatives | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |